LLY: Eli Lilly Partners With Profluent in $2.25 Billion AI-Driven Genetic Med

Eli Lilly Partners With Profluent in $2.25 Billion AI-Driven Genetic Medicine Deal

Apr 28, 2026 12:55 UTC

LLY

Long term

Eli Lilly and Company has announced a strategic partnership with Profluent, an AI-first protein design company, aimed at advancing the development of genetic medicines. The collaboration focuses on the creation of AI-designed enzymes to enhance the precision and scalability of DNA-editing tools. The deal leverages Profluent's proprietary AI protein design models to create recombinases for specific genetic targets. By integrating these AI capabilities with Lilly's established expertise in genetic medicine, the two companies aim to accelerate the discovery of novel therapeutic candidates. The financial terms of the agreement include an upfront payment to Profluent, supplemented by potential payments tied to development and commercial milestones. Additionally, Profluent is entitled to tiered royalties on net sales of any products resulting from the collaboration. The total potential value of the deal is estimated at $2.25 billion. Under the terms of the agreement, Lilly will hold exclusive rights to develop and commercialize the selected candidates. This move signals Lilly's continued investment in cutting-edge biotechnology and AI to maintain its competitive edge in the genetic medicine landscape.

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Eli Lilly Partners With Profluent in $2.25 Billion AI-Driven Genetic Medicine Deal

Sign up free to read the full analysis

Related Articles

PayPal Faces Leadership Turmoil as Valuation Hits Decade Lows

PVL Ex-Dividend Reminder - 4/30/26

NOVTU Ex-Dividend Reminder - 4/30/26

How to Pick a Healthcare Stock That Can Weather Any Market

Stay Ahead of the Markets

Wait — Don't Miss Out!